Chemours: Analysts’ Recommendations after Its 2Q17 Earnings
Analysts’ consensus on Chemours
With eight analysts actively tracking Chemours (CC), 88% of the analysts recommended a “buy,” 12% recommended a “sell,” and none of the analysts recommended a “hold.”
Interested in BCS? Don't miss the next report.
Receive e-mail alerts for new research on BCS
Analysts’ consensus suggests a target price at $50.00—up from the previous target price of $48. It implies a potential return of 6.0% over the closing price as of August 2, 2017.
Why analysts recommended a “buy”
The strong revenue and earnings growth in 2Q17 and an upward revision of the adjusted EBITDA for fiscal 2017 reflects the strong position that the company can deliver in upcoming quarters. The outlook could have influenced most of the analysts to recommend a “buy” on Chemours.
Individual brokerage firms
- After 2Q17, Barclays (BCS) raised Chemours’ target price to $55, which implies a potential return of $16.60%—compared to the closing price on August 2, 2017.
- Jefferies recommended a target price of $60 for Chemours, which implies a potential return of 27.3% based on its closing price of $47.15 as of August 2, 2017.
- J.P. Morgan (JPM) rated Chemours as “overweight” with a target price of $50, which implies a potential return of 6.0%—compared to the closing price on August 2, 2017.
Investors can hold Chemours (CC) indirectly by investing in the iShares U.S. Basic Materials ETF (IYM). IYM has invested 1.60% of its portfolio in Chemours. The fund also provides exposure to stocks like Dow Chemical (DOW) and DuPont (DD) with weights of 11.90% and 11.70%, respectively, as of August 2, 2017.